- Home
- HSDT vs QTTB Comparison
HSDT vs QTTB Comparison
Compare HSDT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | QTTB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 80.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HSDT | QTTB |
|---|---|---|
| Price | $2.17 | $6.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 363.1K | 340.0K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | $91.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.40 |
| 52 Week High | $25.50 | $8.05 |
Technical Indicators
Market Signals| Indicator | HSDT | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 58.59 |
| Support Level | $1.71 | $3.75 |
| Resistance Level | $2.37 | $7.92 |
| Average True Range (ATR) | 0.16 | 0.66 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 81.30 | 79.58 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).